SCHEMBL22130718

SCHEMBL22130718

CS(=O)(=O)n1cc(-c2ccccc2)c2c1C(C#N)=CC(=O)C2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELAVL1 Q15717 7/20 0.54
ALDH1A1 P00352 6/20 0.35
KDM4E B2RXH2 5/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HPGD P15428 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
LMNA P02545 1/20 0.34
CYP3A4 P08684 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GAA P10253 2/20 0.34
GALR3 O60755 1/20 0.34
PTGS2 P35354 4/20 0.33
MAPK1 P28482 1/20 0.33
ALOX5 P09917 1/20 0.32
GLA P06280 1/20 0.32
HTR6 P50406 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22130652 0.86 ELAVL1 (0.58) ELAVL1HTR6L3MBTL1
SCHEMBL22130669 0.82 ELAVL1 (0.64) ELAVL1PTGS2HTR6
SCHEMBL22130635 0.82 ELAVL1 (0.51) ELAVL1ALDH1A1SMN1; SMN2LMNAHTR6
SCHEMBL22130712 0.79 ELAVL1 (0.55) ELAVL1PTGS2ALOX5HTR6L3MBTL1
SCHEMBL22130710 0.79 ELAVL1 (0.55) ELAVL1PTGS2ALOX5HTR6L3MBTL1
SCHEMBL22130636 0.78 ELAVL1 (0.64) ELAVL1ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL22130709 0.78 ELAVL1 (0.54) ELAVL1PTGS2ALOX5HTR6L3MBTL1
SCHEMBL22130711 0.78 ELAVL1 (0.54) ELAVL1PTGS2ALOX5HTR6L3MBTL1
SCHEMBL22130672 0.74 ELAVL1 (0.80) ELAVL1KDM4EKMT2APTGS2MAPK1
SCHEMBL19737481 0.70 ELAVL1 (1.00) ELAVL1PTGS2ALOX5HTR6L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy AZI2, TPMT, TYMS ELAVL1 2765/4885ALDH1A1 229/4885KDM4E 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.